Skip to content

Evaluation of Usefulness of ONS (Oral Nutritional Supplement) in Postoperative Patients with Gastric Cancer

Evaluation of Usefulness of ONS (Oral Nutritional Supplement) in Postoperative Patients with Gastric Cancer - Evaluation of Usefulness of ONS (Oral Nutritional Supplement) in Postoperative Patients with Gastric Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000004650
Enrollment
150
Registered
2010-12-01
Start date
2010-12-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

Postoperatively, intervention with ONS at a dose of approximately 400 kcal/day will be administered and observed from the start of meal to 12 weeks after discharge. We assess a control group in the s

Sponsors

THE UNIVERSITOY OF TOKYO
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Male or female patients aged 20 years and older at the time of informed consent 2)Patients who are able to take orally 3)Patients who will receive radical total gastrectomy for cancer irrespective of technique 4) Patients who will receive radical distal gastrectomy for cancer irrespective of technique 4)Patients who have not received pretreatment for gastric cancer (radiation, chemotherapy, and hormonal therapy etc.) 5)Patients who fully understand the study procedures and have given voluntary written informed consent after a full explanation is given

Exclusion criteria

Exclusion criteria: 1)Patients with ileus 2)Patients with no residual intestinal function 3)Patients with severe liver disorder AST (GOT) or ALT (GPT) ≥ 2.5 times the upper limit of normal at hospital 4)Patients with severe renal disorder Cr ≥ 2.0 mg/dL 5)Patients with abnormal glucose metabolism such as severe diabetes mellitus : HbA1c ≥ 7.0% 6)Patients with allergy to any ingredient of milk, wheat, soy bean, or salmon 7)Pregnant women, women suspected of being pregnant, or lactating women 8)Patients with active double cancer and/or multiple cancer

Design outcomes

Primary

MeasureTime frame
Percent change and amount of change in body weight (amount of change in BMI)

Secondary

MeasureTime frame
1)Percent change and amount of change in grip strength 2)QOL (EORTC QLQ-C30) 3)Percentage of completed chemotherapy (only patients receiving chemotherapy) 4)Nutritional indexes 5)Body composition 6)Occurrence of adverse events of ONS

Countries

Japan,Asia(except Japan)

Contacts

Public ContactHATAO, Fumihiko

THE UNIVERSITOY OF TOKYO Department of Gastrointestinal Surgery

fchobi@gmail.com03-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026